LPA and myocardial ischemia: Nonetheless, the ongoing trials with a non-sense oligonucleotide, pelacarsen [17], or a small RNA silencer, olpasiran [18], would provide conclusive conclusions related to the reduction of Lp(a) to <50 mg/dL in patients with established IHD and elevated Lp(a) levels [19].